‘Too big to care’: Sweep­ing law­suit ac­cus­es Te­va of col­lud­ing with oth­er gener­ic mak­ers to keep prices high

6 years ago
Pharma

They got bounced out of Alex­ion. Now David Hal­lal and Vikas Sin­ha are back with $150M and a fo­cus on cell and gene ...

6 years ago
Financing
Startups

Up­dat­ed: In­ter­change­able biosim­i­lars: FDA fi­nal­izes guid­ance

6 years ago
R&D
FDA+

En­gulfed in le­gal trou­ble, bank­rupt­cy could be the an­swer for opi­oid drug­mak­er In­sys

6 years ago
Pharma

Biotech hits the brakes on their PhI­II piv­otal for a lead an­tibi­ot­ic as in­ves­ti­ga­tors track a high rate of kid­ney ...

6 years ago
R&D

Philo­gen who? A low pro­file but phar­ma-con­nect­ed Ital­ian-Swiss hy­brid steps out with $68M for a fi­nal push over the ...

6 years ago
Financing
R&D

Lam­bast­ed by AIDS ac­tivists about Tru­va­da pric­ing, Gilead of­fers CDC drug sup­ply deal; Fi­bro­Gen MACE mis­com­mu­ni­ca­tion ...

7 years ago
News Briefing

Bi­cy­cle signs on new clin­i­cal ex­ecs in pipeline dri­ve; Howard Stern signs on as Fog­Phar­ma CSO

7 years ago
Peer Review

That feel­ing you get when you hit the fin­ish line, and then set new goals

7 years ago
Editor's note
Bioregnum

Sem­ma goes on a suc­cess­ful ‘fish­ing’ ex­pe­di­tion in its hunt for a di­a­betes cure

7 years ago
R&D

Puma in­vestors fret, as Ner­l­ynx Q1 sales fall un­com­fort­ably short of Wall Street es­ti­mates

7 years ago
Pharma

PhI may still be a killing field of fail­ure but PhI­II suc­cess rates have surged, sig­nal­ing tec­ton­ic shifts in ...

7 years ago
R&D

A new­ly formed biotech launched out of George Da­ley’s Har­vard lab adds glob­al play­ers to its syn­di­cate, bring­ing ...

7 years ago
Startups
R&D

ICER chas­tis­es J&J for over­pric­ing de­pres­sion drug es­ke­t­a­mine ‘where there is such need for treat­ment’

7 years ago
Pharma

Bay­er kicks off a $150M add-on for its cam­pus in Berke­ley

7 years ago
R&D
Cell/Gene Tx

Gilead says on­ly Te­va can mar­ket Tru­va­da gener­ic; Den­ver nar­row­ly votes to de­crim­i­nal­ize "mag­ic mush­rooms"

7 years ago
News Briefing

Push­ing hard for block­buster re­turns, No­var­tis finds PhI­II da­ta to as­sert Mayzent boosts cog­ni­tive pow­ers in MS ...

7 years ago
R&D

Pre­clin­i­cal da­ta on MD An­der­son Can­cer Cen­ter-de­vel­oped drug of­fers hope for Im­bru­vi­ca-re­sis­tant man­tle cell lym­phoma ...

7 years ago
R&D

Once the cen­ter of a pub­lic storm of anger over de­nied drug, Chimerix now can’t even re­cruit pa­tients for their ...

7 years ago
R&D

An­oth­er PhI­II #fail for Bris­tol-My­ers’ star drug rais­es fresh ques­tions about their R&D strat­e­gy as Mer­ck surges ...

7 years ago
R&D

Four biotechs haul in $303M+ from a fresh burst of IPOs

7 years ago
Financing

New study spot­lights a link be­tween block­buster SGLT2 drugs and po­ten­tial­ly lethal gan­grene

7 years ago
R&D

Take­da inks a pair of sales to No­var­tis and J&J for up to $5.7B, hand­ing over 485 staffers

7 years ago
Pharma

List prices in drug ads on TV com­ing as CMS fi­nal­izes rule

7 years ago
Pharma
First page Previous page 935936937938939940941 Next page Last page
A service from the Financial Times